Susquehanna International Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-425,898
| Closed | -$7.66M | – | 11530 |
|
|
2020
Q2 | $7.66M | Sell |
425,898
-212,502
| -33% | -$2.96M | ﹤0.01% | 2452 |
|
|
2020
Q1 | $4.55M | Buy |
638,400
+317,354
| +99% | +$3.96M | ﹤0.01% | 2701 |
|
|
2019
Q4 | $7.67M | Buy |
321,046
+20,965
| +7% | +$578K | ﹤0.01% | 2403 |
|
|
2019
Q3 | $8.05M | Sell |
300,081
-4,902
| -2% | -$138K | ﹤0.01% | 2202 |
|
|
2019
Q2 | $8.27M | Buy |
304,983
+130,038
| +74% | +$4.08M | ﹤0.01% | 2090 |
|
|
2019
Q1 | $6.07M | Sell |
174,945
-85,090
| -33% | -$2.46M | ﹤0.01% | 2239 |
|
|
2018
Q4 | $5.08M | Sell |
260,035
-76,342
| -23% | -$1.57M | ﹤0.01% | 2274 |
|
|
2018
Q3 | $8.96M | Sell |
336,377
-46,983
| -12% | -$1.53M | ﹤0.01% | 2053 |
|
|
2018
Q2 | $14.5M | Buy |
383,360
+15,399
| +4% | +$589K | 0.01% | 1585 |
|
|
2018
Q1 | $12M | Sell |
367,961
-123,059
| -25% | -$5.4M | ﹤0.01% | 1618 |
|
|
2017
Q4 | $23.9M | Buy |
491,020
+214,814
| +78% | +$10.9M | 0.01% | 1126 |
|
|
2017
Q3 | $14.9M | Buy |
276,206
+229,457
| +491% | +$13.5M | 0.01% | 1450 |
|
|
2017
Q2 | $2.63M | Sell |
46,749
-55,669
| -54% | -$2.23M | ﹤0.01% | 3388 |
|
|
2017
Q1 | $4.01M | Sell |
102,418
-24,139
| -19% | -$769K | ﹤0.01% | 2607 |
|
|
2016
Q4 | $2.84M | Buy |
126,557
+37,052
| +41% | +$724K | ﹤0.01% | 3361 |
|
|
2016
Q3 | $2.03M | Buy |
+89,505
| New | +$2.1M | ﹤0.01% | 3548 |
|
|
2016
Q2 | – | Sell |
-94,554
| Closed | -$2.33M | – | 9650 |
|
|
2016
Q1 | $1.93M | Buy |
94,554
+85,663
| +963% | +$2.72M | ﹤0.01% | 3847 |
|
|
2015
Q4 | $457K | Sell |
8,891
-28,025
| -76% | -$1.36M | ﹤0.01% | 6933 |
|
|
2015
Q3 | $1.57M | Sell |
36,916
-13,188
| -26% | -$636K | ﹤0.01% | 4757 |
|
|
2015
Q2 | $2.28M | Buy |
+50,104
| New | +$2.02M | ﹤0.01% | 4429 |
|
|
2015
Q1 | – | Sell |
-39,634
| Closed | -$1.36M | – | 10180 |
|
|
2014
Q4 | $1.12M | Buy |
+39,634
| New | +$1.1M | ﹤0.01% | 5629 |
|
|
2014
Q3 | – | Sell |
-11,015
| Closed | -$290K | – | 10183 |
|
|
2014
Q2 | $321K | Buy |
11,015
+1,539
| +16% | +$37.2K | ﹤0.01% | 8264 |
|
|
2014
Q1 | $245K | Buy |
+9,476
| New | +$253K | ﹤0.01% | 7916 |
|
|
2013
Q4 | – | Sell |
-8,917
| Closed | -$239K | – | 9495 |
|
|
2013
Q3 | $239K | Sell |
8,917
-4,114
| -32% | -$97.9K | ﹤0.01% | 7527 |
|
|
2013
Q2 | $320K | Buy |
+13,031
| New | +$259K | ﹤0.01% | 6707 |
|
Susquehanna International Group's PTLA Position: Q3 2020 in Review
Susquehanna International Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 425,898 shares — an estimated $7.66M sold.
Susquehanna International Group first reported a position in PTLA in Q2 2013 and held it in 25 quarters. The position peaked at $23.9M in Q4 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Susquehanna International Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Susquehanna International Group sold 425,898 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $7.66M.
- Susquehanna International Group first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 25 quarters.
- Susquehanna International Group's Portola Pharmaceuticals, Inc. position peaked at $23.9M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Susquehanna International Group's 13F filing for Q3 2020, filed 16 Nov 2020.